Clinical Trials Browser

Hematologic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Carcinoma, Hepatocellular

Endometrial Neoplasms

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Vulvar Neoplasms

Carcinoma, Renal Cell

Penile Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Renal Cell

Carcinoma, Hepatocellular

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Brain Neoplasms, Neoplasms

Carcinoma, Squamous Cell

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Endometrial Neoplasms

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Vulvar Neoplasms

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Liver Neoplasms

Carcinoma, Renal Cell

Biliary Tract Neoplasms, Cholangiocarcinoma

Neuroendocrine Tumors

Thyroid Neoplasms

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Endometrial Neoplasms

Thyroid Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Carcinoma, Renal Cell

Carcinoma, Hepatocellular, Liver Neoplasms

Advanced Gastric Adenocarcinoma

Carcinoma, Hepatocellular

Triple Negative Breast Neoplasms

Biliary Tract Neoplasms

Biliary Tract Neoplasms Immunotherapy

Carcinoma, Hepatocellular

Carcinoma, Renal Cell

Stomach Neoplasms

Kidney Neoplasms

Uterine Cervical Neoplasms

Advanced Solid Tumor

Carcinoma, Hepatocellular

Thyroid Carcinoma, Anaplastic

Clinical Trials

MK-3475-587

MK-3475-06B

MK-6482-043

FLEX-HCC

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Keynote B59

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

PIERCE

TRIPLE-PATH

QL1706 Plus Lenvatinib in Previously Treated Penile Cancer

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

SAMURAI

GDFATHERHCC01

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

SLIDE-HCC

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

LaPemERLA

LONGIST

MITO VULVA-01

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

HAIC-quad

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

NeoLATC

KEYNOTE-365

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

MAGNATE-S

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

International Multicentric Study ARON-1

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer